Why Are Minorities Less Likely to Be Prescribed GLP-1s?

It may seem like glucagon-like peptide-1 receptor agonists (GLP-1s) are everywhere these days. But these medications aren’t always easy to come by. And, it turns out, whether you’re prescribed one may partly depend on your racial background.
The Data Behind GLP-1 Access
“It’s really concerning. We see disparities in a lot of evidence-based care for a variety of reasons,” says Ajaykumar Rao, MD, an associate professor of medicine and the chief of endocrinology, diabetes, and metabolism at Lewis Katz School of Medicine at Temple University in Philadelphia. “We all need to think about what factors are playing a role in doctors not prescribing GLP-1s for people from these backgrounds.”
Why Black and Latino People Might Not Be Prescribed a GLP-1
What Makes Someone a Good Candidate for a GLP-1
Systemic inequality continues to affect treatment recommendations — even when those same medications can be just as effective for people of all races. In fact, there’s good reason to think Black and Latino people may be particularly good candidates for a GLP-1.
“The presence of cardiovascular disease — such as a history of a heart attack, stroke, or heart failure — are aspects we think about when considering GLP-1s, because there’s proven benefits for reducing all of these events in people with diabetes,” says Dr. Rao. Because of this, he adds, it’s crucial for your physician to take a good health history and uncover any information that could be linked to these conditions.
People who have a high body mass index and a higher A1C level (a measurement of your average blood sugar levels over the past three months) also make good candidates for a GLP-1, especially because other type 2 diabetes medications aren’t always able to lower A1C levels as much as these drugs can, says Rao.
What to Discuss With Your Doctor
If you think you might benefit from taking a GLP-1, don’t hesitate to initiate the conversation with your doctor. And don’t feel like you need to seek out a specialist to do so. “Primary care physicians are in a great position to get people going on these medicines,” says Rao.
Before bringing questions to your doctor, Rao recommends familiarizing yourself with the American Diabetes Association’s Standards of Care, a summary of the organization’s most current recommendations, which is updated annually.
“Reading up on these can help people advocate for themselves in front of their providers,” he says. “Print those or have them on your phone and ask your doctor, ‘Are we following this?’” If the answer is no, ask why.
If your doctor determines that a GLP-1 may work for you, Rao advises asking the following questions, so you know what to expect when taking the meds:
- What are the side effects? “It’s always important to ask this, because you don’t want to read a list of possible side effects on the box when you get home and get scared,” says Rao.
- What might my A1C levels look like? Your provider should be able to estimate what your blood sugar levels may be after three months and after six months.
- How do I administer it? Because many of these medications are injectables, make sure you’re comfortable with how to use them. If you’re not, ask your provider for help or for other options.
How to Make GLP-1s More Affordable
GLP-1s, while effective, are often expensive, even if insurance covers them. “Something could be covered, but then when you go to the pharmacy, you may still have an out-of-pocket cost,” says Rao.
For commercial insurance patients, there are manufacturer-supported cards or copay cards that can reduce costs, he says. If your provider’s connected with a hospital, there may also be an outpatient pharmacy offering a lower out-of-pocket cost.
Finally, Rao suggests looking into patient prescription assistance programs, but he notes that this can require a bit of work. (You or your provider may have to fill out some applications, for example.)
There’s also a generic GLP-1 called liraglutide on the market, which may be available at a lower price. While that medication could be a good fit for you, know that providers should always choose the most appropriate treatment for you and your health, Rao says.
The Takeaway
- GLP-1 medications can significantly improve health outcomes for people with type 2 diabetes and obesity, but research suggests that many minorities are missing out.
- Black and Latino people in particular may benefit from taking a GLP-1: Black and Latino adults are more likely to be diagnosed with diabetes and to have high blood pressure — a risk factor for heart disease — than white people.
- Learning more about these medications, talking with your doctor, and finding ways to make them more affordable can help reduce the racial gap in GLP-1 prescriptions.
- Rodriguez LA et al. Race and Ethnicity and Pharmacy Dispensing of SGLT2 Inhibitors and GLP-1 Receptor Agonists in Type 2 Diabetes. The Lancet Regional Health – Americas. June 2024.
- Statistics About Diabetes. American Diabetes Association.
- Tolbert J et al. Key Facts About the Uninsured Population. KFF. December 18, 2024.
- Funk C. Black Americans’ Views About Health Disparities, Experiences With Health Care. Pew Research Center. April 7, 2022.
- Heart Disease and Black/African Americans. U.S. Department of Health and Human Services Office of Minority Health. September 22, 2023.
- Social Determinants of Health and Chronic Kidney Disease. National Kidney Foundation. January 2, 2023.
- Perkovic V et al. Effects of Semaglutide on Chronic Kidney Disease in Patients With Type 2 Diabetes. The New England Journal of Medicine. July 11, 2024.
- Black Kidney Health Matters. National Kidney Foundation.
- Ashrafi SA et al. Disparities in Healthcare Access Experienced by Hispanic Chronic Kidney Disease Patients: A Cross-Sectional Analysis. Journal of Health, Population and Nutrition. January 31, 2024.

Elise M. Brett, MD
Medical Reviewer
Dr. Brett practices general endocrinology and diabetes and has additional certification in neck ultrasound and fine-needle aspiration biopsy, which she performs regularly in the office. She is voluntary faculty and associate clinical professor at the Icahn School of Medicine at Mount Sinai. She is a former member of the board of directors of the American Association of Clinical Endocrinology. She has lectured nationally and published book chapters and peer reviewed articles on various topics, including thyroid cancer, neck ultrasound, parathyroid disease, obesity, diabetes, and nutrition support.

Laurel Leicht
Author
Laurel Leicht has been a writer and editor for nearly two decades. A graduate of the College of William and Mary and the master's program at the Missouri School of Journalism, she covers a wide range of health and fitness topics, including breast cancer, various chronic conditions, mental health, and cardiovascular health.